Hikma Pharmaceuticals (HIK) Insider Trading & Ownership → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free HIK Stock Alerts GBX 1,949 -24.00 (-1.22%) (As of 06/7/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Hikma Pharmaceuticals (LON:HIK) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage30.62%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)£14,565.44Number OfInsiders Selling(Last 12 Months)0 Get HIK Insider Trade Alerts Want to know when executives and insiders are buying or selling Hikma Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HIK Insider Buying and Selling by Quarter Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. Hikma Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/7/2024Riad MishlawiInsiderBuy736GBX 1,979£14,565.44 (Data available from 1/1/2013 forward) HIK Insider Trading Activity - Frequently Asked Questions Who is on Hikma Pharmaceuticals's Insider Roster? The list of insiders at Hikma Pharmaceuticals includes Deneen Vojta, Douglas Hurt, Riad Mishlawi, and Sigurdur Olafsson. Learn more on insiders at HIK. What percentage of Hikma Pharmaceuticals stock is owned by insiders? 30.62% of Hikma Pharmaceuticals stock is owned by insiders. Learn more on HIK's insider holdings. Which Hikma Pharmaceuticals insiders have been buying company stock? The following insiders have purchased HIK shares in the last 24 months: Deneen Vojta (£17,030), Douglas Hurt (£27,300), and Riad Mishlawi (£14,565.44). How much insider buying is happening at Hikma Pharmaceuticals? Insiders have purchased a total of 3,236 HIK shares in the last 24 months for a total of £58,895.44 bought. More Insider Trading Tools from MarketBeat Related Companies: Indivior Insider Selling Benchmark Insider Selling Alliance Pharma Insider Selling Animalcare Group Insider Selling ECO Animal Health Group Insider Selling Haleon Insider Selling Smith & Nephew Insider Selling ConvaTec Group Insider Selling Dechra Pharmaceuticals Insider Selling EMIS Group Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Top 4 Stocks With Notable Insider Buying3 Small Cap Tech Stocks That Insiders Are Buying3 Stocks Insiders are Buying That Should be on Your RadarInsider Trading is Good News for These Stocks4 Small-Cap Energy Stocks Insiders are Buying This page (LON:HIK) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.